Video Series

Key opinion leaders share their final thoughts on advancing treatments of Dry Eye Disease.

A professional analysis of the potential cost-effective impact of emerging dry eye therapies on the health care system.

Medical professionals explore CSCC and BCC treatment in high-risk, immunocompromised patients—specifically in the setting of organ transplantation.

Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.

Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.

Practical guidance for institutions navigating bispecific therapy integration without prior experience is provided.

Mirna Chehade, MD, MPH, outlines consequences that can stem from delay in diagnosis of eosinophilic esophagitis (EoE), as well as treatment goals, highlighting unique considerations for treatment in children.

Experts provide insights for health care decision makers on the importance of Lp(a) level assessment to help mitigate the risk of cardiovascular disease, including actionable steps for seamless integration.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, provide insights into upcoming Lp(a)-targeted treatments and current management strategies for improved cardiovascular outcomes.

Dr. Yeu examines risk factors for Demodex blepharitis, including patients with diabetes and immunosuppression.

A medical expert highlights the impact of bronchiectasis diagnosis on quality of life for patients and their caregivers.

Providers delve into considerations for continuation of optimal care when patients receiving bispecific therapy transition between care settings.

Medical experts discuss strategies for optimal implementation of bispecific therapies in cancer care.

Considerations for enhancing bispecific drug effectiveness through strategic EMR utilization in healthcare are explored.

A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.

Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; compare emerging therapies and traditional treatments for dry eye disease.

Medical experts explore recent therapies in the treatment of dry eye disease.

The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC.

Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.

Factors that differentiate Demodex blepharitis apart from other lid margin and ocular surface diseases with overlapping signs and symptoms are examined.

Notable signs and symptoms distinguishing bronchiectasis from other pulmonary disease states are discussed.

Mirna Chehade, MD, MPH, discusses eosinophilic esophagitis (EoE), detailing its immune-mediated nature and age-dependent symptoms, emphasizing that in children, symptoms can manifest as feeding difficulties and failure to thrive.

Amy Nguyen Howell, MD, MBA, highlights the importance of data collection, analysis, and the new ICD-10-CMZ codes in understanding and resolving health disparities in diabetic macular edema patient care.

Experts discuss strategies for integrating Lp(a) testing into clinical practice across organizations, leveraging new therapies, education, and quality measures for improved patient care.

Experts discuss the integration of Lp(a) testing into cardiovascular risk assessment, and refining preventive strategies and statin use in specific groups.

The panelists provide their final takeaways from the discussion surrounding treatment of MDS.

Potential issues associated with insurance coverage and ways to navigate these challenges are discussed by medical experts.

Experts examine the economic burdens on the health care system, payers, and patients, based on associated costs with dry eye disease.